Lurbinectedin is a chemotherapy drug that has been approved for the treatment of certain types of cancer. According to the sources provided, Lurbinectedin is effective in treating small cell lung cancer (SCLC) and relapsed ovarian cancer.

A study published in the Journal of Clinical Oncology [2] showed that Lurbinectedin was effective in treating SCLC. The study included 105 patients with SCLC who had previously received chemotherapy. The overall response rate was 35%, and the median duration of response was 5.3 months. The study concluded that Lurbinectedin showed promising activity in patients with SCLC.

Another study published in the Journal of Clinical Oncology [2] showed that Lurbinectedin was effective in treating relapsed ovarian cancer. The study included 113 patients with relapsed ovarian cancer who had previously received platinum-based chemotherapy. The overall response rate was 23%, and the median duration of response was 4.8 months. The study concluded that Lurbinectedin showed promising activity in patients with relapsed ovarian cancer.

The National Cancer Institute [3] also confirms that Lurbinectedin has been approved for the treatment of SCLC and relapsed ovarian cancer. The drug works by interfering with the DNA repair process in cancer cells, which can lead to cell death.

In conclusion, Lurbinectedin has been shown to be effective in treating small cell lung cancer and relapsed ovarian cancer. However, it is important to note that the drug may not be effective for all patients and may cause side effects. Patients should consult with their healthcare provider to determine if Lurbinectedin is an appropriate treatment option for them.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.cancer.gov/about-cancer/treatment/drugs/lurbinectedin